Screener
Vera Therapeutics VERA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $621,739 | $734,733 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,909 | $21,898 |
| Accrued expenses and other liabilities, current | 31,240 | 31,557 |
| Total current liabilities | 45,149 | 53,455 |
| Long-term debt | 75,029 | 74,838 |
| Other liabilities, noncurrent | 1,864 | 1,919 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's accounts payable?
- Vera Therapeutics (VERA) reported accounts payable of $13.91M in Q1 2026.
- How has Vera Therapeutics's accounts payable changed year-over-year?
- Vera Therapeutics's accounts payable increased by 50.2% year-over-year, from $9.26M to $13.91M.
- What is the long-term trend for Vera Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Vera Therapeutics's accounts payable has grown at a 83.3% compound annual growth rate (CAGR), from $5.51M to $62.27M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Vera Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude